Search Results for: RALA

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel ACTB actin beta
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Gap junction degradation
  • Formation of annular gap junctions
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • HATs acetylate histones
  • Prefoldin mediated transfer of substrate to CCT/TriC
  • Folding of actin by CCT/TriC
  • EPHB-mediated forward signaling
  • EPH-ephrin mediated repulsion of cells
  • Adherens junctions interactions
  • Adherens junctions interactions
  • Recycling pathway of L1
  • Recycling pathway of L1
  • VEGFA-VEGFR2 Pathway
  • Interaction between L1 and Ankyrins
  • Interaction between L1 and Ankyrins
  • Cell-extracellular matrix interactions
  • B-WICH complex positively regulates rRNA expression
  • RHO GTPases activate IQGAPs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • MAP2K and MAPK activation
  • UCH proteinases
  • DNA Damage Recognition in GG-NER
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Clathrin-mediated endocytosis
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Quercetin
  • Phenethyl Isothiocyanate
  • Other phagocyte defects, including the following eight diseases: Chediak-Higashi syndrome; Griscelli syndrome, type 1 (GS1); Griscelli syndrome, type 2 (GS2); Griscelli syndrome, type 3 (GS3); beta-actin deficiency; Neutrophil-specific granule deficiency; Myeloperoxidase deficiency; Glucose 6-phosphate dehydrogenase deficiency; Shwachman syndrome
Novel AKAP10 A-kinase anchoring protein 10
  • Factors involved in megakaryocyte development and platelet production
Novel C1QC complement C1q C chain
  • Initial triggering of complement
  • Classical antibody-mediated complement activation
  • Regulation of Complement cascade
  • Cetuximab
  • Etanercept
  • Palivizumab
  • Daclizumab
  • Bevacizumab
  • Zinc
  • Copper
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Classic complement pathway component defects, including the following eight diseases: C1q alpha-chain deficiency; C1q beta-chain deficiency; C1q gamma-chain deficiency; C1r deficiency; C1s deficiency; C2 deficiency; C3 deficiency; C4 deficiency
Novel GCK glucokinase
  • Regulation of Glucokinase by Glucokinase Regulatory Protein
  • Regulation of gene expression in beta cells
  • Defective GCK causes maturity-onset diabetes of the young 2 (MODY2)
  • Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)
  • Glycolysis
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Beta-D-Glucose
  • 2-amino-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide
  • 3-[(4-fluorophenyl)sulfanyl]-N-(4-methyl-1,3-thiazol-2-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide
  • 2-(methylamino)-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide
  • 2-AMINO-4-FLUORO-5-[(1-METHYL-1H-IMIDAZOL-2-YL)SULFANYL]-N-(1,3-THIAZOL-2-YL)BENZAMIDE
  • Maturity onset diabetes of the young (MODY)
  • Permanent neonatal diabetes mellitus (PNDM)
Novel HOXA2 homeobox A2
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • Regulation of expression of SLITs and ROBOs
Novel INHBA inhibin subunit beta A
  • Signaling by Activin
  • Signaling by Activin
  • Glycoprotein hormones
  • Antagonism of Activin by Follistatin
ARF1 ADP ribosylation factor 1
  • Synthesis of PIPs at the plasma membrane
  • Synthesis of PIPs at the Golgi membrane
  • Nef Mediated CD4 Down-regulation
  • trans-Golgi Network Vesicle Budding
  • MHC class II antigen presentation
  • Lysosome Vesicle Biogenesis
  • Golgi Associated Vesicle Biogenesis
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
  • Intra-Golgi traffic
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • 1,3-Propanediol
  • Guanosine-3'-monophosphate-5'-diphosphate
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • Brefeldin A
  • Myristic acid
  • Glycerin
CALM1 calmodulin 1
  • CaMK IV-mediated phosphorylation of CREB
  • CaMK IV-mediated phosphorylation of CREB
  • Calmodulin induced events
  • Cam-PDE 1 activation
  • CaM pathway
  • Platelet degranulation
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • PKA activation
  • DARPP-32 events
  • Synthesis of IP3 and IP4 in the cytosol
  • Calcineurin activates NFAT
  • Calcineurin activates NFAT
  • eNOS activation
  • Transcriptional activation of mitochondrial biogenesis
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Stimuli-sensing channels
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Ca2+ pathway
  • Reduction of cytosolic Ca++ levels
  • Sodium/Calcium exchangers
  • Unblocking of NMDA receptors, glutamate binding and activation
  • CREB1 phosphorylation through the activation of Adenylate Cyclase
  • CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
  • CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
  • Ras activation upon Ca2+ influx through NMDA receptor
  • Smooth Muscle Contraction
  • Smooth Muscle Contraction
  • Activation of Ca-permeable Kainate Receptor
  • Uptake and function of anthrax toxins
  • VEGFR2 mediated vascular permeability
  • VEGFR2 mediated cell proliferation
  • Phase 0 - rapid depolarisation
  • Ion homeostasis
  • CLEC7A (Dectin-1) induces NFAT activation
  • CLEC7A (Dectin-1) induces NFAT activation
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
  • RAF activation
  • RAF/MAP kinase cascade
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Glycogen breakdown (glycogenolysis)
  • Glycogen breakdown (glycogenolysis)
  • Protein methylation
  • Extra-nuclear estrogen signaling
  • Loss of phosphorylation of MECP2 at T308
  • Regulation of MECP2 expression and activity
  • Ion transport by P-type ATPases
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Activation of RAC1 downstream of NMDARs
  • Activation of RAC1 downstream of NMDARs
  • Activation of AMPK downstream of NMDARs
  • Long-term potentiation
  • Long-term potentiation
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated IL10 synthesis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Chlorpromazine
  • Cinchocaine
  • Nicardipine
  • Fluphenazine
  • Isoflurane
  • Trifluoperazine
  • Loperamide
  • Perphenazine
  • Phenoxybenzamine
  • Felodipine
  • Melatonin
  • Promethazine
  • Pimozide
  • Nifedipine
  • Bepridil
  • Calcium
  • Aprindine
  • Deacetoxyvinzolidine
  • tert-butanol
  • Trimethyllysine
  • N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
  • Prenylamine
  • Flunarizine
  • (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE
  • Myristic acid
  • Calcium citrate
  • Calcium citrate
  • Calcium citrate
  • Calcium Phosphate
  • Calcium Phosphate
  • Calcium Phosphate
  • Calcium levulinate
  • Calcium phosphate dihydrate
  • Calcium phosphate dihydrate
  • Calcium phosphate dihydrate
CNKSR2 connector enhancer of kinase suppressor of Ras 2
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
CTCF CCCTC-binding factor
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
EXOC1 exocyst complex component 1
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Insulin processing
  • VxPx cargo-targeting to cilium
EXOC2 exocyst complex component 2
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Insulin processing
  • VxPx cargo-targeting to cilium
EXOC3 exocyst complex component 3
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Insulin processing
  • VxPx cargo-targeting to cilium
EXOC4 exocyst complex component 4
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Insulin processing
  • VxPx cargo-targeting to cilium
EXOC5 exocyst complex component 5
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Insulin processing
  • VxPx cargo-targeting to cilium
EXOC6B exocyst complex component 6B
EXOC7 exocyst complex component 7
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Insulin processing
  • VxPx cargo-targeting to cilium
EXOC8 exocyst complex component 8
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Insulin processing
  • VxPx cargo-targeting to cilium
FLNA filamin A
  • Platelet degranulation
  • GP1b-IX-V activation signalling
  • Cell-extracellular matrix interactions
  • RHO GTPases activate PAKs
  • OAS antiviral response
  • Artenimol
  • Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
  • Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia
  • Periventricular nodular heterotopia (PVNH)
  • FG syndrome (FGS); Opitz-Kaveggia syndrome
GLS2 glutaminase 2
  • Glutamate Neurotransmitter Release Cycle
  • TP53 Regulates Metabolic Genes
  • Glutamate and glutamine metabolism
  • Glutamic acid

Page 1 out of 2 pages